Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IMMUNOLOGY

Editing naive CD4+ T cells

Nature Methods volume 19, pages 36–37 (2022)Cite this article

Subjects

As last we can edit the immune system’s sleeping giants, as CRISPR tools advance into the world of naive CD4+ T cells.

The advent of CRISPR gene editing to manipulate the DNA blueprint of genes and functionally characterize resulting phenotypes has rapidly advanced the field of molecular biology. It was only a matter of time before immunologists would grab hold of these tools to tackle some of our most difficult-to-control human diseases. HIV researchers have taken advantage of these emerging molecular tools to manipulate the viral genome and to mobilize the immune system to thwart the virus.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Evolution of CRISPR–Cas9 technology toward gene editing in resting lymphocytes.

References

  1. Chun, T.-W. et al. Nat. Med. 1, 1284–1290 (1995).

    Article  CAS  Google Scholar 

  2. Siliciano, J. D. et al. Nat. Med. 9, 727–728 (2003).

    Article  CAS  Google Scholar 

  3. Albanese, M. et al. Nat. Methods https://doi.org/10.1038/s41592-021-01328-8 (2021).

  4. Geng, X., Doitsh, G., Yang, Z., Galloway, N. L. & Greene, W. C. Gene Ther. 21, 444–449 (2014).

    Article  CAS  Google Scholar 

  5. Baldauf, H. M. et al. Nat. Med. 18, 1682–1687 (2012).

    Article  CAS  Google Scholar 

  6. Jinek, M. et al. eLife 2, e00471 (2013).

    Article  Google Scholar 

  7. Schumann, K. et al. Proc. Natl Acad. Sci. USA 112, 10437–10442 (2015).

    Article  CAS  Google Scholar 

  8. Stevenson, M. Nat. Med. 9, 853–860 (2003).

    Article  CAS  Google Scholar 

  9. Sowd, G. A. et al. Proc. Natl Acad. Sci. USA 113, E1054–E1063 (2016).

    Article  CAS  Google Scholar 

  10. Laguette, N. et al. Nature 474, 654–657 (2011).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Z.M.N. is supported by an HHMI International Research Scholar award (grant 55008743 to Z.M.N.) and the US National Institutes of Health (NIAID) (R01AI145305 to Z.M.N., R37 AI67073 to BDW). A.O.P is supported by a Bill and Melinda Gates Foundation Grand Challenges grant (INV-016491 to Z.M.N. and grant 55008743 to Z.M.N.). This work used computational facilities at the Africa Health Research Institute (AHRI).

Author information

Authors and Affiliations

  1. Africa Health Research Institute (AHRI), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa

    Andrea Olga Papadopoulos & Zaza Mtine Ndhlovu

  2. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA

    Zaza Mtine Ndhlovu

Authors
  1. Andrea Olga Papadopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zaza Mtine Ndhlovu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zaza Mtine Ndhlovu.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Papadopoulos, A.O., Ndhlovu, Z.M. Editing naive CD4+ T cells. Nat Methods 19, 36–37 (2022). https://doi.org/10.1038/s41592-021-01332-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41592-021-01332-y

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research